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ABSTRACT
Our previous data supported a role for the Stearoyl-CoA desaturase (SCD5) 
in protection against malignancy, whereby it appears to functionally modify tumor 
stroma impairing tumor spread. SCD5 is significantly expressed in primary melanoma, 
but becomes barely detectable at tumor advanced stages. Looking for the regulatory 
mechanisms underlying SCD5 reduced expression during melanoma progression, we 
demonstrated a significantly lower stability of SCD5 protein as well as the direct 
targeting of SCD5 mRNA by the oncogenic miR-221&222 in metastatic cell lines. 
Moreover, our results indicated the existence of a negative feedback loop between 
SCD5 and miR-221&222, in good agreement with their opposite functions. Also, we 
showed how SCD5 re-expression and the direct supplementation of its main product 
oleic acid (OA) can drive advanced melanoma cell lines toward differentiation and 
reversion of the epithelial-mesenchymal (EMT)-like process, eventually inducing a 
less malignant phenotype. Indeed, SCD5 re-established the sensitivity to all-trans 
retinoic acid in A375M metastatic melanoma, associated with increased levels of 
Tyrosinase, melanin production and reduced proliferation. As evidenced by the 
correct modulation of some key transcription factors, SCD5 managed by favoring a 
partial mesenchymal-to-epithelial (MET) transition in in vitro studies. Interestingly, 
a more complete MET, including E-cadherin re-expression correctly localized at cell 
membranes, was obtained in in vivo xenograft models, thus indicating the requirement 
of direct contacts between tumor cells and the surrounding microenvironment as well 
as the presence of some essential factors for SCD5 complete function.
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 INTRODUCTION
Lipid composition affects membrane functionality, 
endosomal trafficking and provides a platform for cell 
signaling. Perturbation of this composition can have 
profound effects in different cell systems, including 
cancer cells [1]. Fatty acids are characterized by different 
chain length, linkage and saturation level, the latter 
characteristic influencing cell malignancy. Saturated 
fatty acids (SFA) (mostly 16:0 palmitic and 18:0 stearic 
acids) are desaturated by Stearoyl CoA desaturases 
(SCDs), SCD1 and SCD5 in humans. The action of these 
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enzymes produce monounsaturated fatty acids (MUFA), 
essentially 16:1 palmitoleic and 18:1 oleic fatty acids, 
playing a role in the increment of cell membrane fluidity, 
but more important in the maintenance of the growth rate 
of tumor cells [2–4]. Different studies suggest a more 
complex picture on fatty acid role when we look at cancer 
cell ability to metastasize. For example in human oral 
carcinomas, the cell population able to metastasize express 
high levels of CD36 fatty acid receptor and diets rich in 
saturated palmitic acid  increase the metastatic potential 
of this cell subpopulation [5]. On the contrary, in breast 
cancer cells with Her-2/neu oncogene amplification, the 
MUFA oleic acid suppresses Her-2/neu overexpression, 
which, in turn, synergistically interacts with anti-Her-2/
neu immunotherapy by promoting apoptotic cell death [6]. 
SCD1, the main known human desaturase, is 
up-regulated in the majority of cancers and it is one 
of the central targets of growth factors and hormones 
that regulate key cell cycle events [7]. Differently from 
SCD1, the pathophysiological role of SCD5 remains 
basically unknown. Although the mechanism of action 
on lipid substrates appears the same, tissues and levels of 
expression are different. If SCD1 is ubiquitously present, 
SCD5 is essentially expressed in pancreas and in the central 
nervous system [4, 8]. During melanoma progression SCD5 
expression was down-regulated, being highly expressed in 
primary compared to more advanced melanomas, where 
it is barely detectable. According to SCD5 antimetastatic 
function, its restoration reduces the capability to 
disseminate of both the A375M human melanoma and 
4T1 murine mammary carcinoma cell lines evaluated in in 
vivo models. The reduced malignancy of SCD5 expressing 
cells was triggered by increased level of oleic acid, 
intracellular pH reduction with consequent failure of both 
vesicle movement toward the cell periphery and release of 
protumoral proteins, as Secreted Protein Acidic and Rich in 
Cysteine (SPARC) and Collagen IV [9, 10]. 
SPARC expression has been linked with aggressive, 
mesenchymal-like phenotypes in different human cancers, 
including melanoma, where it is known to contribute to 
phenotype changes during the Epithelial-Mesenchymal 
Transition (EMT) process when cells, losing their 
characteristics, gain mesenchymal features, become motile 
and eventually increase their dissemination capability [11]. 
The EMT event is regulated by different transcription 
factors and a hallmark of this functional change is the lack 
of E-cadherin expression. Literature data describe in depth 
the key proteins involved in the progression of epithelial 
tumors, but the functions of these factors are less clearly 
elucidated in non-epithelial contexts, like melanoma. It is 
also important to consider the general reversibility of this 
process.
A pivotal role has recently been provided for the 
Microphthalmia-associated transcription factor (MITF), 
master regulator of melanocyte differentiation and 
pigmentation genes [12], also involved in the control of 
different plasticity states. Several other genes, beyond 
MITF, can be associated with cell modification and 
dissemination [13], including SPARC, whose suppression 
reduces the tumorigenic potential in mouse xenograft 
assays [14–16].
In the present study we searched for the regulatory 
mechanisms and factors underlying SCD5 expression in 
differently staged melanoma cell lines. Also, in view of 
our previous studies demonstrating the SCD5-dependent 
intracellular retention of SPARC and considering the known 
involvement of SPARC itself in supporting a mesenchymal-
like phenotype, we looked for the possible SCD5 capability 
in reversing the EMT-like process in melanoma. Actually, 
SCD5 re-expression in advanced melanomas was able 
to favor a less-invasive, more differentiated phenotype 
associated with a partial remodulation of the EMT. 
Interestingly this reversion appeared more complete in 
xenograft models, thus addressing the action of some 
essential constituents available and/or activated only in vivo.
RESULTS
Regulation of SCD5 expression in melanoma
Our previous studies showed SCD5 significantly 
higher expression in primary than in metastatic 
melanoma cell lines where it was barely detectable. 
Immunohistochemistry analysis performed on human 
melanoma bioptic specimens confirmed the strong 
positivity in primary cutaneous melanoma and the faint 
signal in metastatic samples (Figure 2B and ref [9]). More 
important, the enforced expression of SCD5 in the A375M 
metastatic melanoma cell line was able to significantly 
reduce its aggressiveness including the capability of these 
cells to produce metastases in an in vivo model of Nu/Nu 
mice [9]. 
On this basis, we investigated the regulatory 
mechanisms underlying SCD5 down-regulation associated 
with melanoma progression. Hence we evaluated the 
possible involvement of some key epigenetic mechanisms, 
as DNA methylation and/or histone modifications 
considering that SCD5 might be included in the number of 
tumor suppressor genes epigenetically inactivated during 
tumorigenesis [17]. Actually, utilizing demethylating 
drugs, as 5-aza-2′-deoxycytidine (5AzaCdR), or drugs 
that inhibit class I and/or class II histone deacetylases 
(HDACs), as the pan-inhibitor trichostatin A, we did not 
obtain significant increases of SCD5 expression levels. 
In the A375M advanced melanoma, SCD5 appears only 
slightly unblocked by 5-aza alone whereas no effects 
at all seemed associated with acetylation. The expected 
induction of the cyclin-dependent kinase inhibitor p21, 
included as a positive control, confirmed the effectiveness 
of the treatments (data not shown). 
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We then looked for different SCD5 mRNA and/or 
protein stabilities associated with melanoma progression. 
The mRNA half-life was evaluated in presence of the 
mRNA synthesis inhibitor Actinomycin D (ActD), whereas 
the protein degradation time was assessed by treating with 
the protein synthesis inhibitor cycloheximide (CHX). 
For this analysis, we selected the early primary Me1007 
and the metastatic A375 cell lines, as representative of 
initial and advanced stages. Although, the basal amounts 
of SCD5 mRNA were different between Me1007 and 
A375, according to the progression stages, being highly 
expressed in the first and low but detectable in the latter 
(Supplementary Figure 1A), we did not observe significant 
differences in their degradation rates (Supplementary 
Figure 1B). In both cell lines the amount of SCD5 mRNA 
was approximately halved 15 hours after the ActD 
treatment. Conversely, the degradation time of SCD5 
protein,  evaluated in the same cell lines up to 18 hours 
after CHX action, evidenced significantly accelerated 
protein degradation of SCD5 in the metastatic A375 cell 
line (half-life ~90 min), compared with the slow rate in 
Me1007 primary melanoma (half-life of approximately 12 
hours) (Figure 1A, 1B). 
Finally, we examined whether SCD5 regulation 
would possibly go through proteasome ubiquitination. 
Notably, treatment with the proteasome inhibitor MG-
132 blocked SCD5 degradation in A375 cells, whereas it 
did not seem to affect the protein level in Me1007 cells 
(Figure 1C), at least up to 15h, thus further indicating a 
different regulatory mode of this pathway. 
Essentially, we detected a significantly more 
stable SCD5 protein in primary compared to metastatic 
melanoma cell lines, in good agreement with the 
expression pattern detected in our panel of cell lines [9]. 
SCD5 is a direct target of miR-221&222
Considering the inverse functional correlation 
between SCD5 and miR-221&222 during melanoma 
progression [9, 18] and the predicted presence of one 
conserved binding site for these miRs in the 3′ Untranslated 
Region (3′UTR) of SCD5 mRNA (http://www.targetscan.
com) (Figure 3A), we hypothesized the involvement of 
these microRNAs (miRs) in SCD5 regulation. According 
to this hypothesis, SCD5 levels appeared compatible with 
miR-221&222 targeting evaluated by qRealTime PCR and 
western blot in melanoma cell lines (Figure 2A) as well 
as by in situ hybridization and immunohistochemistry on 
primary bioptic samples (Figure 2B). SCD5 was highly 
expressed in primary tumors, where this couple of miRs 
was barely or not detectable, whereas the opposite pattern 
was visible in advanced melanomas (Figure 2A, 2B).
The expression pattern of SCD5 was then analyzed 
in Me1007 melanoma enforced to lentivirally express 
miR-221 or miR-222. SCD5 resulted down-regulated 
at mRNA and protein levels by both miRs (Figure 3B). 
Accordingly, in antagomiR-treated A375M metastatic 
melanoma cells, we observed the induction of SCD5 
after miR-221 and/or -222 inhibitions (Figure 3C). It is 
interesting to note the higher effectiveness associated with 
the abrogation of both miRs on SCD5 re-expression since 
they share the seed sequence as well as most of their target 
genes and functional roles.
We then tested whether miR-221&222 were able 
to directly target SCD5 using a reporter dual luciferase 
assay. To this end the 3′UTR region of SCD5, containing 
wild type or mutated miR-221&222 binding sequences 
(Figure 3A), was cloned downstream to the Renilla open 
reading frame in a modified psi-Check promoter vector. 
The initial co-transfection experiments were performed in 
the 293FT cell line. As shown, transfection of miR-221 
and/or miR-222, in presence of SCD5 wild type 3′UTR 
induced a significant decrement of luciferase activity 
(roughly 40%) that was higher when transfections were 
carried out in presence of both miRs (approximately 50%). 
As a control of specificity, point mutations inserted in the 
miR binding site restored the Renilla levels (Figure 3D). A 
similar miR-dependent repression of SCD5 was obtained 
when the luciferase assays were performed by transfecting 
the 3′UTR regions of SCD5, either wt or mutated, into 
the Me1007 melanoma cell line stably overexpressing 
miR-221 or miR-222. Results, obtained in comparison 
with empty vector transduced control cells (Figure 3E), 
confirmed SCD5 as a novel direct target of miR-221&222. 
Indeed SCD5 down-regulation appears functional to 
melanoma progression. 
SCD5 increases melanoma differentiation 
through the up-modulation of MITF transcription 
factor and the down-modulation of miR-221&222
The microphthalmia-associated transcription factor 
(MITF) is a master regulator of melanocyte development, 
differentiation, function and survival [19]. Interestingly, 
different levels of MITF are reported to exert different 
effects in melanogenesis, where this protein functions as 
a rheostat determining the various functional states [20].
Actually western blot and IF analyses demonstrated 
the capability of SCD5 enforced expression to increase 
MITF, in turn inducing Tyrosinase and increasing the 
level of melanin in both SCD5-transduced A375M and 
Me1402/R cell lines (Figure 4A–4C). These data indicate 
the capability of SCD5 to promote the differentiation 
program (Figure 4C). 
Our previous studies reported MITF down-regulation 
as a consequence of miR-221&222 targeting of c-KIT 
and consequently of its downstream pathway, leading to 
melanogenesis [18]. In addition it was recently reported 
that MITF represses miR-221&222 promoter and in 
turn its absence in advanced melanomas contributes to 
miR-221&222 up-regulation, thus effectively initiating 
melanoma invasion [21]. Considering the reduced spreading 
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of melanoma cells overexpressing SCD5 [9] and the 
increased expression of MITF, we evaluated whether miR-
221&222 levels were modulated by the presence of SCD5. 
Indeed, qRealTime PCR confirmed a 40–50% reduction 
of miR-221&222 expressions in A375M and Me1402/R 
melanomas overexpressing SCD5 (Figure 4D). The 
reduced levels of miR-221&222 were correctly associated 
with increased amount of their target, the cyclin-dependent 
kinase inhibitor 1B, p27Kip1/CDKN1B (Figure 4E). 
All together these results indicate the existence of a 
negative feedback loop between SCD5 and miR-221&222.
SCD5 restores sensitivity to ATRA treatment in 
metastatic melanoma
In several cancers, as leukemia and breast cancer, 
all trans retinoic acid (ATRA) or its derivatives are 
successfully utilized, whereas their action is often 
ineffective in melanoma [22]. Here we evaluated 
whether SCD5 might enhance melanoma sensitivity to 
ATRA treatment. To this end, we analyzed the possible 
functional outcomes on A375M melanoma, known to 
be ATRA resistant, when transduced either with SCD5 
Figure 1: Evaluation of SCD5 protein stability and proteasoma-dependent degradation in melanoma cell lines. (A) 
Me1007 early primary and A375 metastatic melanoma cell lines were treated with Cycloheximide (CHX) up to 18 hours and SCD5 
stability evaluated by western blot analysis at the indicated time points. (B) Densitometric analysis of normalized samples shows the 
significantl longer half-life of SCD5 protein in Me1007 compared with A375 cell line. (C) Western blot analysis shows the MG132-
dependent accumulation of SCD5 in A375, but not in Me1007 cells. The cell cycle inhibitor p27Kip1, whose degradation is known to be 
proteasome dependent, was included as a control. 
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or with the Tween empty vector. These melanoma cells 
were then compared for their proliferative rates and the 
expression levels of some possible effectors. Cell growth 
proliferation of SCD5-transduced A375M cells resulted 
reduced in comparison to Tween control cells, and 
was further decreased when cells were co-treated with 
ATRA. As expected, in view of their resistance, the same 
treatment had no effect on control cells (Figure 5A). We 
then evaluated by qRealTime PCR and/or western blot 
whether SCD5 could modulate the expression level of a 
number of key factors potentially driving the effects of 
ATRA supplementation. Actually results showed interest 
and coherent changes, as we detected the up-regulation of 
Sex-Determining Region Y-Box 9 Protein (SOX9) which, 
already induced by SCD5, was further up-regulated by 
ATRA (Figure 5B). In addition we observed a significant 
SCD5-dependent down-regulation of Preferentially 
Expressed Antigen in Melanoma (PRAME) (Figure 
5B), a melanoma antigen causally implicated in tumor 
transformation and acting as a dominant inhibitor of the 
retinoic acid receptor (RAR) pathway [23]. Looking for 
the possible effects on melanogenesis, we analyzed the 
levels of MITF and Tyrosinase, as differentiative factors, 
and of the cell cycle inhibitor p27Kip1, detecting their 
increase associated with SCD5 enforced expression and 
their additional rise due to ATRA treatment (Figure 5C, 
5E). Accordingly, the 40% decrease of miR-221&222 
consequent to SCD5 overexpression went down to 50% 
after ATRA treatment (Figure 5D). Thus, the up-regulation 
of SCD5 expression in human melanomas appear able to 
restore their sensitivity to ATRA treatment slowing down 
their cell growth and favoring differentiation.
Figure 2: SCD5 and miR-221&222 expressions are inversely correlated in melanoma progression. (A) The inverse 
correlations between miRs and their target SCD5 are shown. Relative expression values, reported as arbitrary units, were obtained by 
qRealtime PCR and densitometric analysis of western blot. (B) In situ hybridization of miR-221&222 and immunohistochemistry of 
SCD5 performed on human bioptic specimens. One primary melanoma, Clark’s level III, and one lymph node metastasis are shown as 
representative. Bar, 100 μm. Scrambled and RNU6B correspond to negative and positive controls of ISH, respectively.
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SCD5 drives a partial EMT to MET-TF switch in 
human melanoma
The process of EMT is associated with modulation 
of transcription factors, surface receptors and secreted 
molecules, resulting in cytoskeletal reorganization and 
acquisition of new properties that contribute to tumor 
progression and metastases formation [24].
In our model the SCD5-associated spreading 
reduction correlates with the diminished secretion in the 
tumor microenvironment of SPARC that is known to modify 
the extracellular matrix (Supplementary Figure 2A, 2B). 
As a consequence of SPARC reduced secretion into the 
surrounding microenvironment, SCD5-transduced A375M 
melanoma and 4T1 mammary carcinoma cells, respectively 
injected into athymic Nu/Nu immunocompromised 
Figure 3: miR-221&222 direct targeting of SCD5. (A) Schematic seed pairing between SCD5 3′UTR and hsa-miR-221&222 
is shown by bars. The seed sequence is indicated in upper case bold letters, while lower case letters represent mutated nucleotides. (B) 
qRealTime PCR and representative western blot analysis of SCD5 down-regulation in miR-221&222- vs Tween-transduced Me1007 
primary melanoma cell line. (C) qRealTime PCR of A375M metastatic melanoma transfected with antagomiR-221&222 (αmiR), alone or 
in combination, confirmed the correct miR down-regulation and the consequent increase of SCD5 expression in co-trasfection condition. 
Tubulin (TUB) was used as loading control and αmiR-133 as a negative control. Luciferase reporter assays, performed in (D) the 293FT 
transfected cell line and (E) Me1007 melanoma lentivirally infected with miR-221 or miR-222. Mutated nucleotides are shown in (A). 
Results were compared with a no targeting oligomer in the first experiment and with empty vector (EV)-transduced cells in the second one. 
(*p < 0.05, **p < 0.01). 
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or immunocompetent syngeneic BALB/c mice were 
associated with decreased stromal deposition, eventually 
preventing their metastasization potential [9].
As in melanoma the EMT-like process is influenced 
by the action of SPARC [11], we evaluated whether 
SCD5 restored expression might be able to modulate the 
transcription factors playing a key role in this program. 
According to the reduced malignancy of SCD5 
overexpressing cells, western blot analysis on purified 
nuclear and cytoplasmic extracts from SCD5-transduced 
and control cells together with immunofluorescence 
data showed a significant reduction of Zinc Finger 
E-Box Binding Homeobox 1 (ZEB1) and Snail Family 
Transcriptional Repressor 2 (SNAI2/SLUG) paralleled 
by ZEB2 up-regulation. Also, the FOS Like 1, AP-1 
Transcription Factor Subunit (FRA-1), an AP-1 family 
member whose expression has been associated with 
melanoma progression, was virtually abrogated (Figure 
6A, 6B) [25]. Thus, we checked for the possible induction 
of E-cadherin, whose functional loss at the cell-cell 
junctions represents one of the hallmarks of the EMT 
[26]. We then not only assessed E-cad expression level, 
but also its localization, both in vitro in melanoma cell 
lines and in vivo in tumor nodules recovered from Nu/
Nu mice subcutaneous (s.c.) injected either with A375M/
SCD5 or A375M/Tween cells. Although no significant 
increase of E-cadherin amount was detected by IF 
analysis in A375M/SCD5 cells cultured in vitro, we were 
able to highlight an incomplete relocation of E-cadherin, 
present as cytoplasmic spots at the external boundary 
of the cells, differently from the mostly perinuclear 
distribution observed in control cells (Supplementary 
Figure 3C top panel). Interestingly, as demonstrated 
by western blot and IF, these small dots were increased 
when melanoma cells were treated with 5AzaCdR, 
according to the methylation-dependent suppression of 
E-cadherin in advanced melanoma [27]. Once again, 
despite increased expression, E-cadherin did not appear 
to be able to reach the cell membrane (Supplementary 
Figure 3A and 3C bottom panel). Immortalized human 
keratinocytes (HaCaT) were used as positive controls of 
E-cadherin expression and cell membrane localization 
(Supplementary Figure 3B). 
More striking results were obtained in the in vivo 
model. In fact western blot analysis of proteins extracted 
from A375M/SCD5 tumor nodules, in addition to Snail 
Family Transcriptional Repressor 1 (SNAI1/SNAIL) 
and Twist Family BHLH Transcription Factor (TWIST) 
reduction and ZEB2 up-regulation, showed the induction 
of E-cadherin (Figure 6C). More important, IHC analysis, 
besides confirming the presence of human melanoma 
cells highly positive for SCD5, showed the induction 
Figure 4: SCD5 overexpression drives melanoma cell lines toward differentiation. Western blot and immunofluorescence 
analyses show a sharp increase of MITF and Tyrosinase (TYR) expression in SCD5-transduced cells compared to Tween controls in 
(A) A375M and (B) Me1402/R cell lines. Bar, 10 μm. Tubulin (TUB) was used to normalize. (C) Evaluation of melanin content shows 
its increase in SCD5-trasduced melanoma cell lines compared to the control ones. (D) qRealTime PCR show miR-221&222 reduced 
expression in SCD5 overexpressing melanoma cell lines, associated with (E) increased protein level of their target p27Kip1 (*p < 0.05). 
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Figure 5: Combined effects of SCD5 overexpression and ATRA supplementation. (A) Cell growth proliferation evaluated at 
the indicated time points. Representative WB analysis (bottom) and densitometric quantification (upper) of (B) SOX9 and PRAME and 
(C) MITF and Tyrosinase. qRealTime PCR confirmed the ATRA-dependent down-regulation of (D) miR-221 and -222 as well as (E) up-
modulation of their target p27Kip1. (*p < 0.05, **p < 0.01 for A375M/SCD5 vs Tween-control); °p < 0.05 for A375M/SCD5 plus ATRA 
exogenous supplementation vs untreated A375M/SCD5).
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of E-cadherin, but also its correct localization at cell 
membrane levels (Figure 6D). 
All together these changes indicate that SCD5 
restored expression reduces the metastatic potential of 
melanoma cells by favoring a Mesenchymal-to-Epithelial 
transition.
Effects of oleic acid supplementation
Considering that in melanoma SCD5 plays its 
main role by converting stearic into oleic acid (OA) and 
in view of the reported capability of OA to mimic SCD5 
functional effects reducing melanoma malignancy [9], we 
finally evaluated whether the exogenous supplementation 
of OA could be per se active on EMT-reversion as well 
as on melanoma differentiation. The A375M/Tween cells 
were treated with increasing concentrations of OA (20 
to 100 µM) up to 3 days and analyzed by western blot. 
Results showed a significant modulation of some key 
EMT-TFs, specifically SNAI2/SLUG reduction paralleled 
by ZEB2 up-regulation (Supplementary Figure 4A). In 
addition, the induction of MITF and Tyrosinase expression 
paralleled by miR-221&222 down-modulation, showed 
the influence of OA also on melanoma differentiation 
(Supplementary Figure 4A, 4B). All together these 
results indicate the capability of OA to mimic the effects 
produced by SCD5 overexpression (Figure 6A).
DISCUSSION
The treatment of metastatic melanoma still 
represents a challenging issue. Besides many other factors, 
fatty acids are known to affect growth response of cancer 
cells [28]. Specifically, the ratio of stearate to oleate plays 
a role in controlling bilayer fluidity, in turn influencing 
membrane functions [29].
Our previous studies showed the antimetastatic 
role of the desaturating enzyme SCD5 in both human 
melanoma and murine mammary carcinoma cells [9]. 
Interestingly, SCD5 enforced expression displayed a 
preferential action in desaturating stearic more than 
palmitic acid, thus prevalently inducing oleic acid 
Figure 6: SCD5 overexpression favors a mesenchymal to epithelial transition. Evaluation of EMT-TFs levels in purified 
cytoplasmic and nuclear extracts from A375M/SCD5 vs Tween control cells by (A) western blot and (B) immunofluorescence. Bar, 10 μm. 
Tumor nodules derived from Nu/Nu mice s.c. injected with the same cell lines analyzed by (C) western blot and (D) Immunohistochemistry 
confirmed the SCD5-dependent regulation of some key EMT-TFs. Bar, 100 μm.
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production. In view of SCD5 decrease associated with 
melanoma progression, we looked for the mechanisms 
possibly underlying its regulation. Indeed, a shorter protein 
half life of SCD5 was evidenced in advanced melanoma 
compared to primary ones (Figure 1A), supporting the 
presence of biological processes aimed at preventing 
accumulation of SCD5 in metastatic cells. Besides this 
first line regulation, we demonstrated SCD5 to be finely 
tuned as a novel target of the oncomir-221&222, in 
agreement with the contribution of this couple of miRs 
to the invasive potential of melanoma cells through the 
repression a number of tumor suppressor and negative 
regulators of cell growth (Figures 2 and 3) [30]. 
The functional involvement of SCD5 in some 
circuitries of the oncogenic transformation was confirmed 
by the induction of key differentiation and antineoplastic 
genes consequent to its restored expression in advanced 
melanomas. Indeed, WB or IF analyses performed in both 
A375M and Me1402/R cell lines enforced to express 
SCD5, confirmed on one side the rise of MITF and TYR, 
involved in the melanogenesis program (Figure 4), on 
the other a partially reversed Epithelial-to-Mesenchymal 
Transition, further contributing to the antimetastatic action 
of SCD5 (Figure 6). 
Considering SCD5 as part of the differentiation 
program, we explored the possibility of its role in restoring 
the sensitivity to differentiating agents, like ATRA, in 
the highly resistant A375M cell line [31]. This drug, 
successfully utilized in the treatment of acute promyelocytic 
leukemia [32], is under exploited in other tumors, including 
melanoma, due to early development of resistance. 
According to the lower malignancy associated with SCD5 
re-expression, the growth rate of the A375M/SCD5 cells 
was slightly reduced by the transgene and further down-
regulated by ATRA supplementation. Conversely, no 
significant effects were obtained by ATRA on A375M/
Tween control cells (Figure 5). Investigating ATRA 
response mechanisms, we focused on PRAME, recently 
reported as a dominant repressor of RAR signaling in 
AML, and SOX9, a transcription factor significantly down-
regulated in melanoma specimens [33, 34]. Indeed, SCD5 
overexpression in metastatic melanoma was sufficient 
to reduce PRAME, in turn activating MITF and SOX9, 
which were further increased by ATRA (Figure 5B, 5C). 
The observed antiproliferative effect was supported by the 
accumulation of p27Kip1 cell cycle inhibitor as a combined 
product of ATRA treatment and miR-221&222 down-
modulation (Figure 5D, 5E). Thus, we can consider SCD5 
as an upstream factor able to directly or indirectly regulate 
proliferation and differentiation in melanoma. Notably, 
PRAME was also reported to be modulated through 
the prostaglandin enzymatic pathway starting from the 
arachidonic acid (AA), a precursor of the proinflammatory 
cytokines prostaglandin E2 and leukotriene B4, whose 
metabolism is competitively inhibited by oleic acid (OA) 
[35]. Interestingly, these data are in good agreement 
with our results showing the preferential action of SCD5 
toward stearic-to-oleic acid conversion as confirmed by the 
increased desaturation index (18:1/18:0) paralleled by a 
5-fold reduction of AA, evaluated by GC/MS ([9] and data 
not shown).
One of the key antimetastatic roles associated with 
SCD5 restored expression in melanoma was the strong 
intracellular retention of SPARC coupled with its impaired 
secretion (Supplementary Figure 2 and [9]). SPARC 
overexpression was associated with highly aggressive 
human melanomas and its secreted fraction underlies the 
communication between tumor cells and surrounding 
microenvironment [36]. As SPARC is involved in the 
transition from epithelial to mesenchymal phenotypes, we 
have hypothesized the possible contribution of SCD5 in 
reversing the EMT-like process described in melanoma [37]. 
In line with Denecker [38], which showed ZEB1 
and ZEB2 inverse modulation and the presence of ZEB2 
as a positive prognostic factor for melanoma patients, we 
observed the SCD5-dependent up-regulation of ZEB2 
paralleled by reduced amounts of ZEB1 (Figure 6A, 
6B). It was reported that ZEB2 regulates MITF levels to 
control melanocyte differentiation and that Slug and ZEB1 
are potent repressors of E-cadherin, in turn enhancing 
migration and invasion. Although we did not find Twist 
reduction, ZEB1 down-modulation in parallel to ZEB2 
and MITF up-modulation seems to be sufficient to restart 
melanoma cell differentiation program [39]. 
It is also important to highlight that the in vitro 
OA supplementation was able to recapitulate the actions 
of SCD5 in controlling the MET switch and inducing a 
more differentiated phenotype in A375M/Tween cells 
(Supplementary Figure 4). This result is in agreement 
with growing data evidencing that the Mediterranean 
diet, partly through extra-virgin olive oil and its main 
component OA, exerts some protection in different form 
of cancer, including melanoma [40]. 
Finally, we have to evidence the results obtained 
in vivo in tumor nodules recovered from athymic Nu/
Nu immunocompromised mice s.c. injected, either with 
SCD5- or empty vector-transduced A375M melanoma 
cells. Differently from in vitro studies displaying 
only a partial EMT reversion associated with SCD5 
(Supplementary Figure 3), tumors overexpressing SCD5 
showed a correct modulation of the main EMT-TFs, 
including E-cadherin induction. IHC, besides confirming 
the presence of human melanoma cells positive for SCD5, 
showed evident nests with a clear induction of E-cadherin 
correctly localized at cell membranes (Figure 6C, 6D).
These data are aligned with the requirement of 
microenvironmental factors sustaining SPARC-induced 
EMT, as reported in breast cancer where was demonstrated 
a functional interplay between myeloid-derived suppressor 
cells and the extracellular matrix [41].
All together these results demonstrate the lack of 
SCD5 as central to melanoma progression. Indeed, at 
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advanced melanoma stages, as a consequence of SCD5 
restored expression we evidenced MITF up-regulation 
paralleled by miR-221&222 decreases. Hence, in view 
of the negative cross-regulation between MITF and the 
oncomir-221&222 [18, 21] and considering the direct 
targeting of SCD5 by miR-221&222 themselves, we 
might suggest a self-sustaining circuitry connecting these 
molecules that, in presence of SCD5, favors the MITF 
differentiative side, eventually moving the balance from 
tumor progression toward a less malignant phenotype 
(Figure 7). Last of all our data indicate the possibility 
of considering oleic acid or its derivatives for cancer 
prevention thus including them in the number of adjuvant 
therapeutic agents.
MATERIALS AND METHODS
Cell lines and transduction
Human melanoma cell lines used in the current study 
(see Supplementary Information Supplementary Table 1) 
were stabilized from surgical specimens obtained from 
primary and metastatic tumors (Istituto Nazionale Tumori, 
Milan-Italy. The A375 cell line was from the American 
Type Tissue Collection (Rockville, MD, USA) and its 
metastatic variant A375M was kindly provided by Dr. R. 
Giavazzi (Istituto Mario Negri, Bergamo, Italy). Normal 
human epidermal melanocytes from foreskin were obtained 
from Promocell (Heidelberg, Germany).  Melanoma 
cell lines were authenticated according to standard short 
tandem repeat (STR)-based genotyping (Biological Bank 
e Cell Factory, IRCCS San Martino-IST National Institute 
for Cancer Research Genoa, Italy).  The HaCaT cell line, 
immortalized human keratinocytes used as positive control 
for E-cadherin expression, was kindly provided by Dr. F. 
Facchiano (Istituto Superiore di Sanità, Rome-Italy).
Overexpression of SCD5 in Me1402/R and A375M 
and of miR-221&222 in Me1007 melanoma cell lines was 
obtained by using a lentiviral vector system, as reported 
([9, 18] and Supplementary Figure 5). Chemically modified 
antisense oligonucleotides (antagomirs) have been used to 
inhibit miR-221 and -222 expressions in vitro (Dharmacon 
Inc., Lafayette, CO, USA). According to our previously 
reported data, antagomir-133a was used as a non-targeting 
Figure 7: Schematic depicts showing the main SCD5-dependent regulation. The effects of ATRA treatment were evaluated on 
the A375M melanoma, known to be ATRA resistant, transduced either with SCD5 or with the Tween empty vector. This scheme and the 
corresponding representative IF images show the absence of effect derived by ATRA treatment on A375M control cells and the ATRA-
based differentiation of A375M/SCD5 cells, confirming their restored sensitivity to retinoic acid. In addition the key SCD5-dependent 
molecules are shown.  indicates “induction” and  “repression”.
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negative control [18]. Transfections were performed using 
Lipofectamine 2000 (Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. 
Culture conditions
Human melanoma cell lines derived from tumors 
at different stages of progression have been cultured as 
described before [9].
The early primary Me1007 and the metastatic A375 
cell lines were treated with actinomycin D (2 μg/mL), 
cychloeximide (CHX, 50 μg/mL) and MG132 (10 μM) 
(Sigma-Aldrich, Saint Louis, MO, USA) at different time 
points to evaluate SCD5 mRNA and protein stabilities and 
proteasome-dependent SCD5 degradation pathway.
A375M cells, transduced either with Tween 
empty vector or with SCD5, were treated for 72 hours 
with 5-aza-2′-deoxycytidine (5AzaCdR, 2.5 and 5 μM) 
(Sigma-Aldrich) for epigenetic analyses. All-trans retinoic 
acid (Sigma-Aldrich) was used in the same cell lines at 
10–5/10–6 M at day 1, 3 and 7 of culture for proliferation 
index evaluation (colorimetric assay XTT-based Roche 
Molecular Biochemicals, Mannheim, Germany) and 
differentiation marker analyses. Finally, A375M were 
cultured with oleic acid (SIGMA Aldrich) for 72 h and 
subsequently processed for molecular analyses. Selected 
doses of OA, ranging between 20 and 100 μM OA, were 
tested and then used looking for the effects on EMT and 
differentiation processes. 
RNA extraction and qRealTime PCR 
Total RNA was extracted by using the NucleoSpin 
miRNA kit according to the manufacturer’s specifications 
(Macherey-Nagel GmbH & Co. KG. Düren, Germany). 
qRealTime PCR was performed by the TaqMan 
Technology (Applied Biosystems, Foster City, CA, 
USA), using the ΔΔCt method. Commercial ready-to-
use primers/probe mixes (Assays on Demand Products, 
Life Technologies) are listed: miR-221: #000524; miR-
222: #000525; SCD5v1 #Hs01125695_m1, p27Kip1 
#Hs00153277_m1. MiR-221&222 and SCD5 expression 
levels were normalized by using snRNA U6 (#001973) 
and GAPDH (#4326317E) assays, respectively.
Western blot and immunofluorescence analysis
Western blots were performed according to standard 
procedures. Total proteins were isolated from cell lysates 
or from tumor nodules by using NP40 cell lysis buffer 
and separated by the precast NuPAGE polyacrylamide gel 
system (Life Technologies Carlsbad, CA, USA). Where 
indicated, nuclear and cytoplasmic proteins were purified 
and analyzed following standard protocols. Protein 
concentration was measured by the Bradford protein assay 
(Biorad Hercules, CA, USA). The expression levels were 
quantified using the AlphaView software (ProteinSimple 
San Josè CA USA).
Immunofluorescence analysis was run according to 
standard procedures. Briefly, semi-confluent cells were 
fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) 
and subsequently permeabilized and saturated at room 
temperature. After incubations with primary and specific 
fluorophore-conjugated secondary antibodies (Alexa 
Fluor, Molecular Probes Eugene, OR, USA), slides were 
mounted with SlowFade anti-fade reagent containing 
DAPI (Molecular Probes, Eugene, OR, USA). Cellular 
staining was analyzed by Olympus F1000 laser-scanning 
confocal microscopy (Olympus, Tokyo, Japan).
Melanin content evaluation
Melanin content was measured in duplicate at least 
twice for each cell line as previously described [42]. 
Briefly, melanoma cells were lysed in NaOH (1N) and the 
relative melanin content determined by optical density at 
402 nm by using fluorometry (Victor X3, Wallac–Perkin-
Elmer 2030 software v. 4.00). 
Immunohistochemical and in situ hybridization 
analyses
For in vivo assays, empty vector- or SCD5-
transduced A375M cells in exponential growth phase 
were subcutaneously (s.c.) injected at the dose of 106 
cells into adult athymic nude mice, minimum n = 5 mice/
group (Charles River, Calco, Italy). After evaluation 
of tumor growth, nodules were isolated for molecular 
analyses [9]. Specifically, paraffin embedded murine 
tumor nodules were treated for SCD5 and E-cadherin 
immunohystochemical studies. Serial sections were 
subjected to heat-mediated antigenic retrieval (pH 9.0 
Tris–EDTA buffer), signals revealed with a polymeric 
system (Novolink, Max Polymer Detection System, Leica 
Biosystems, Wetzlar, Germany), and visualized using 
AECt High Sensitivity Substrate Chromogen Ready-to- 
Use (Dako Cytomation Liquid AEC Substrate Chromogen 
System, Agilent Technologies Company, Santa Clara, 
CA, USA). Concerning, IHC staining of SCD5 on bioptic 
melanoma, five cutaneous primary (superficial spreading 
melanoma, Clarks level III) and five lymph nodal 
metastatic samples were embedded in paraffin, sectioned 
and pretreated with Sodium Citrate pH 6.0buffer for 
heat-mediated antigenic retrieval, then combined with a 
standard ABC technique (Vectastain Rabbit ABC Elite Kit 
Vector Laboratories INC. Burlingame, CA, USA). Slides 
were counterstained with hematoxylin and evaluated 
under a Nikon optical microscope (Nikon Eclipse E1000 
equipped with a Nikon DXM 1200 digital camera with 
dedicated acquisition software (Nikon ACT-1 v. 2.1; 
Nikon Instruments, Campi Bisenzio, Florence-Italy). 
Serial sections from the same bioptic human melanoma 
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specimens were subjected to In Situ Hybridization to 
evaluate miR-221&222 expression levels by using 
miRCURY LNA microRNA ISH Optimization kit (FFPE) 
(Exiqon, Vedbaek, Denmark). Specifically we utilized 
miR-221 (#18115-15), miR-222 (#38499-15) and RNU6B 
(#699002-340) and Scrambled (#699004-360) sequences, 
as positive and negative controls, respectively. Specimens 
were obtained with patient informed consent from the 
archives of the Human Pathology Section, University of 
Palermo. Sampling and handling of human tissue material 
was carried out in accordance with the ethical principles 
of the Declaration of Helsinki. 
Renilla activity assays
For Renilla reporter experiments, a 551-bp fragment 
of the SCD5 3′ UTR containing the predicted miR-221 and 
miR-222 binding sites was amplified by PCR from normal 
human genomic DNA using a JumpStart™ AccuTaq™ 
LA DNA Polymerase (Sigma-Aldrich,). The putative 
SCD5 seed starts at nt 2780 of the SCD5 sequence (NCBI 
Reference Sequence: NM_001037582.2). The primers 
utilized were: Forward 5′  GGTGTATAACTCTGACATG 
3′  and Reverse 5′  CAGTTTACACATTACCAGTG 3′ for 
the wild type, Forward 5′  AAG TGA TCg TTA TGcAtC 
TTC 3′  and Reverse 5′  TCC AGA AGaTgC ATA AcG 
3′  for the mutated seed (lower case letters indicate the 
mutated nucleotides). After sequence analysis, the amplified 
region was subcloned, either wild type or mutated, in the 
psiCHECK 2 vector (Promega, Madison, WI, USA) 
immediately downstream to the stop codon of the Renilla 
gene. The 293FT and Me1007 cell lines were transfected 
combining 40 ng of psiCHECK-3′UTR plasmid and 50 
pmol of stability-enhanced miR-221 and/or miR-222 
oligonucleotides or no targeting RNA control (Dharmacon 
Inc., Lafayette, CO, USA) with Lipofectamine 2000 (Life 
Technologies, Carlsbad, CA, USA). The Renilla activity 
was measured by using the Dual Luciferase assay (Promega 
Madison, WI, USA) normalized on the Luciferase level. The 
wt psiCHECK/SCD5 3′UTR cotransfected with the control 
non targeting oligonucleotide was considered as 100%. 
List of utilized antibodies
SLUG (sc-166476), Tyrosinase (sc-20035), SOX9 
(sc-20095), Fra-1 (clone D-3, sc-376148), nucleolin 
C23 (sc-8031) and ZEB1 (sc-25388) (Santa Cruz 
Biotechnology, INC, Dallas, TX, USA), Snail (#3895) 
and p27Kip1 (#2552) (Cell Signaling Technology, 
Leiden, Netherlands), Microphthalmia (Ab-1, #OP126L, 
Calbiochem Thermo Fisher, Waltham, MA, USA), Twist 
(clone 2C1a #ab50887 AbCam, Cambridge, UK), PRAME 
(TA309818, OriGene, Rockville, MD, USA), ZEB2 
(HPA003456, Atlas Antibodies) and SPARC (OSN4.2, 
#M124 from Takara, Kusatsu, Japan) were used in 
accordance to the manufacturer’s instructions. A mouse 
monoclonal and a rabbit monoclonal Abs were utilized 
against E-Cadherin (clone 36 BD #610181, Transduction 
Laboratories and clone 24E10, Cell Signaling Technology, 
Leiden, Netherlands #3195). A specific polyclonal rabbit 
antibody was generated against a human SCD5 synthetic 
peptide (aa 313-327) (Eurogentec Group, Liege, Belgium). 
β-actin (Clone AC-15 #A5441) and α-Tubulin (clone B-5-
1-2 #T5168 (Sigma Aldrich St. Louis, MO, USA) were 
used as loading controls. 
Statistical analysis
Unless indicated otherwise, all data are presented 
as mean ± standard deviation (SD) and results are 
representative of at least three independent experiments. 
Statistical analysis was performed using t-test, with p < 
0.05 deemed statistically significant.
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